Support groundbreaking Israeli cancer research

Why ICRF?

Superb Scientists

Israel has the highest concentration of scientists and physicians per capita

Cost-effective research

Funding scientists in Israel has 30% less overhead costs than North American research

Institution Neutral

Funding goes to scientists at all of Israel's top biomedical research centers

Targeted Funding

ICRF directly funds individual vetted scientists, rather than "bricks and mortar"

ICRF Funded Researcher publishes paper in Nature

Yinon Ben-Neriah, ICRF Funded Researcher publishes paper in Nature: The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic Somatic mutations in p53, which inactivate the tumour-suppressor function of p53 and often confer oncogenic gain-of-function properties, are very common in cancer.
Preview article here.

New approach for overcoming melanoma's resistance to anti-cancer drugs

Melanoma often presents a rapid resistance to molecular anti-cancer therapies. Although there have been advances in targeted and immunotherapy melanoma treatments in recent years, a substantial percentage of patients fail to respond or develop resistance to such therapies. Read article here.

Yinon Ben-Neriah, ICRF Funded Researcher publishes paper in Nature: The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic Somatic mutations in p53, which inactivate the tumour-suppressor function of p53 and often confer oncogenic gain-of-function properties, are very common in cancer.
Preview article here.

HELP US FUND CANCER RESEARCH!

Scientific Discoveries

ribbon

p53 gene tumor suppressor

Demonstrated that the p53 end acts as a tumor suppressor - one of the hallmark discoveries in cancer in the 20th century.

The Philadelphia Chromosome

Identified the structure of the Philadelphia Chromosome, the first genetic linkage identified in leukemia. This lead to the development of Gleevec, one of the first targeted cancer therapies.

Doxil®

This cancer drug works overtime to treat ovarian, breast and AIDS-related cancers.

RAD 51

Used to identify the likelihood of breast cancer occurring in women who carry the BRCA 2 gene.

The Ubiquitin System

Our discovery led to development of the miracle drug Velcade® for treatment of multiple myeloma.

Israel Winning the Nobel Prize

ICRF-funded professors Avram Hershko and Aaron Ciechanover won for their discovery of the ubiquitin system. Their research resulted in the development of the drug Velcade® named “The Top Medical Breakthrough of 2003” by the Wall Street Journal.

Improved Cancer Treatment

ICRF scientists have discovered improved chemo-therapies and advanced techniques in bone marrow transplantation that have improved the survival rates and eased the suffering of many people battling cancer.

Events

Date to be confirmed

Revolving Tables

Our signature NextGen event is back and we’re bringing the...

view event

Date to be confirmed

George Knudson Oakdale Golf Tournament

In memory of George Knudson, golf for the cure this year! ...

view event

Jan 31

ICRF Presents: Unplugged

  We're bringing ICRF Presents to you! ICRF Pres...

view event

Date to be confirmed

Bike for the Fight at Home!

Thanks for making our #bffathome the best Bike for the Fight...

view event

Date to be confirmed

Women of Action

Recognize outstanding and driven women in our community! ...

view event